Personalis’s liquid biopsy is a part of a rising marketplace for minimal residual illness assays, checks that search for any remaining most cancers cells after the preliminary therapy. Tempus AI has been the business companion on this Personalis take a look at since 2023.
The put up Anticipating Large Take a look at Development in Most cancers & Extra, Tempus AI Strikes $1.5B Deal to Purchase Personalis appeared first on MedCity Information.
